When GrB expressions of these B cell subsets were investigated, in the whole CD19+ B cell population, significantly enhanced GrB expression was observed in the whole group of pSS patients (median (min–max): 5.225 (0.41–28.1)% versus 3.69 (0.04–7.29)%, resp., p = 0.0121) and in all subgroups of patients (pSS glandular: median (min–max): 5.505 (0.41–28.1)% versus 3.69 (0.04–7.29)%, resp., p = 0.0261; pSS EGMs: median (min–max): 4.735 (0.73–22.34)% versus 3.69 (0.04–7.29)%, resp., p = 0.0486), compared to the values measured in the healthy controls (Figure 1). This evidence concerns the gene CD19 and peeling skin syndrome.